SG11201606652PA - Solid forms of an ion channel modulator - Google Patents

Solid forms of an ion channel modulator

Info

Publication number
SG11201606652PA
SG11201606652PA SG11201606652PA SG11201606652PA SG11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA SG 11201606652P A SG11201606652P A SG 11201606652PA
Authority
SG
Singapore
Prior art keywords
ion channel
solid forms
channel modulator
modulator
solid
Prior art date
Application number
SG11201606652PA
Other languages
English (en)
Inventor
Anna Chiu
Olga V Lapina
Petinka I Vlahova
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201606652PA publication Critical patent/SG11201606652PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201606652PA 2014-02-13 2015-02-12 Solid forms of an ion channel modulator SG11201606652PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461939640P 2014-02-13 2014-02-13
PCT/US2015/015652 WO2015123434A1 (en) 2014-02-13 2015-02-12 Solid forms of an ion channel modulator

Publications (1)

Publication Number Publication Date
SG11201606652PA true SG11201606652PA (en) 2016-09-29

Family

ID=52597268

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606652PA SG11201606652PA (en) 2014-02-13 2015-02-12 Solid forms of an ion channel modulator

Country Status (16)

Country Link
US (1) US9273038B2 (es)
EP (1) EP3105227A1 (es)
JP (1) JP2017505788A (es)
KR (1) KR20160118358A (es)
CN (1) CN105980380A (es)
AR (1) AR102804A1 (es)
AU (1) AU2015217129A1 (es)
BR (1) BR112016018464A2 (es)
CA (1) CA2881544A1 (es)
EA (1) EA201691360A1 (es)
HK (1) HK1226397A1 (es)
IL (1) IL246959A0 (es)
MX (1) MX2016010563A (es)
SG (1) SG11201606652PA (es)
TW (1) TW201613908A (es)
WO (1) WO2015123434A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CN1845918A (zh) * 2003-07-02 2006-10-11 沃泰克斯药物股份有限公司 可用作电压-门控离子通道调节剂的嘧啶
PT2464645T (pt) * 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
UY34171A (es) * 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
NZ627942A (en) * 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
US20150225383A1 (en) 2015-08-13
IL246959A0 (en) 2016-09-29
EP3105227A1 (en) 2016-12-21
EA201691360A1 (ru) 2017-07-31
MX2016010563A (es) 2016-12-12
CA2881544A1 (en) 2015-08-13
HK1226397A1 (zh) 2017-09-29
KR20160118358A (ko) 2016-10-11
US9273038B2 (en) 2016-03-01
TW201613908A (en) 2016-04-16
AU2015217129A1 (en) 2016-08-11
BR112016018464A2 (pt) 2017-08-08
WO2015123434A1 (en) 2015-08-20
JP2017505788A (ja) 2017-02-23
AR102804A1 (es) 2017-03-29
CN105980380A (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
IL283582A (en) ror - gamma modulators
HK1256599A1 (zh) ROR-γ的調節劑
IL286669A (en) Compounds and methods for modulating tmprss6 expression
EP3183346A4 (en) Channel modulators
EP3800963C0 (en) FREE CHANNEL EVALUATION PROCEDURE AT MASTER DEVICE LEVEL
IL257026A (en) Solid state forms of eluxadoline
SI3524234T1 (sl) Trdne oblike sofosbuvira
EP3127016A4 (en) Provable geo-location
GB201418182D0 (en) Ion modification
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
GB201904142D0 (en) Improved method of FT-IMS
GB201418395D0 (en) Cyclo-depolymerisation of polybutadiene
ZA201804342B (en) Channel section
EP3100230A4 (en) Segments of contacts
HK1226397A1 (zh) 離子通道調節劑的固體形式
GB2546014B (en) Ion source
PL3111151T3 (pl) Sposób działania obrotowego pieca do wytwarzania spoiw hydraulicznych
SG11201600348XA (en) Insulator target
SG11201607445QA (en) Methods of modulating wars2
HK1243457A1 (zh) 通道調節劑
PT3377106T (pt) Modulação da ciliogénese
IL250976A0 (en) Tests for a broadcast channel
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201418511D0 (en) Ion source